You are here: Home » PTI Stories » National » News
Business Standard

Laurus Labs gets Sebi's go ahead for IPO

Press Trust of India  |  New Delhi 

Drug ingredients maker Laurus Labs has received markets regulator Sebi's go ahead to float an initial public offering.

Hyderabad-based firm had filed IPO papers with in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.



According to draft papers, the public issue comprises fresh issue of shares worth Rs 300 crore and an offer for sale of 24,844,240 equity scrips by the existing shareholders, including Warburg Pincus group and Eight Roads Ventures.

Proceed of the issue would be utilised towards payment of loans and for general corporate purposes.

The issue is being managed by Kotak Mahindra Capital Company, Citigroup Global Markets India, Jefferies and Capital Markets.

Prior to that, Aster DM Healthcare, which runs hospitals, filed its draft papers with the markets regulator in June. Another healthcare firm, Centre For Sight, has already received clerance from for its IPO.

Besides, several healthcare companies have successfully launched their IPOs. These include diagnostics chains Dr Lal PathLabs and Thyrocare Technologies and hospital chain Narayana Hrudayala.

Laurus Labs is a leading research and development driven pharma company in India, with a leadership position in generic active pharmaceutical ingredients for select, high-growth therapeutic areas of anti-retrovirals and Hepatitis C.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Laurus Labs gets Sebi's go ahead for IPO

Drug ingredients maker Laurus Labs has received markets regulator Sebi's go ahead to float an initial public offering. Hyderabad-based firm had filed IPO papers with Sebi in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer. According to draft papers, the public issue comprises fresh issue of shares worth Rs 300 crore and an offer for sale of 24,844,240 equity scrips by the existing shareholders, including Warburg Pincus group and Eight Roads Ventures. Proceed of the issue would be utilised towards payment of loans and for general corporate purposes. The issue is being managed by Kotak Mahindra Capital Company, Citigroup Global Markets India, Jefferies India and SBI Capital Markets. Prior to that, Aster DM Healthcare, which runs hospitals, filed its draft papers with the markets regulator in June. Another healthcare firm, New Delhi Centre For ... Drug ingredients maker Laurus Labs has received markets regulator Sebi's go ahead to float an initial public offering.

Hyderabad-based firm had filed IPO papers with in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.

According to draft papers, the public issue comprises fresh issue of shares worth Rs 300 crore and an offer for sale of 24,844,240 equity scrips by the existing shareholders, including Warburg Pincus group and Eight Roads Ventures.

Proceed of the issue would be utilised towards payment of loans and for general corporate purposes.

The issue is being managed by Kotak Mahindra Capital Company, Citigroup Global Markets India, Jefferies and Capital Markets.

Prior to that, Aster DM Healthcare, which runs hospitals, filed its draft papers with the markets regulator in June. Another healthcare firm, Centre For Sight, has already received clerance from for its IPO.

Besides, several healthcare companies have successfully launched their IPOs. These include diagnostics chains Dr Lal PathLabs and Thyrocare Technologies and hospital chain Narayana Hrudayala.

Laurus Labs is a leading research and development driven pharma company in India, with a leadership position in generic active pharmaceutical ingredients for select, high-growth therapeutic areas of anti-retrovirals and Hepatitis C.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Laurus Labs gets Sebi's go ahead for IPO

Drug ingredients maker Laurus Labs has received markets regulator Sebi's go ahead to float an initial public offering.

Hyderabad-based firm had filed IPO papers with in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.

According to draft papers, the public issue comprises fresh issue of shares worth Rs 300 crore and an offer for sale of 24,844,240 equity scrips by the existing shareholders, including Warburg Pincus group and Eight Roads Ventures.

Proceed of the issue would be utilised towards payment of loans and for general corporate purposes.

The issue is being managed by Kotak Mahindra Capital Company, Citigroup Global Markets India, Jefferies and Capital Markets.

Prior to that, Aster DM Healthcare, which runs hospitals, filed its draft papers with the markets regulator in June. Another healthcare firm, Centre For Sight, has already received clerance from for its IPO.

Besides, several healthcare companies have successfully launched their IPOs. These include diagnostics chains Dr Lal PathLabs and Thyrocare Technologies and hospital chain Narayana Hrudayala.

Laurus Labs is a leading research and development driven pharma company in India, with a leadership position in generic active pharmaceutical ingredients for select, high-growth therapeutic areas of anti-retrovirals and Hepatitis C.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard